A Study of ABT-751 in Patients With Colorectal Cancer

ABSTRACT: The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with colorectal cancer. Patients will receive ABT-751 by mouth daily for 21 days. Patients will be off drug for 7 days before starting the next cycle of drug.

DISEASE(S): Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2010121 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR